No abstract available.
Drug Therapy* ; Leukemia, Myeloid, Acute* ; Nausea* ; Vomiting*

No abstract available.
Drug Therapy, Combination* ; Humans ; Leukemia, Myeloid, Acute*

No abstract available.
Drug Therapy* ; Humans ; Leukemia, Myeloid, Acute* ; Mucormycosis*

Background: Acute myelogenous leukemia (AML) is the most common disease of malignant hemopathy in adult. Although induction therapy induced the long complete remissions, but complications of this intensive therapy is very serious. Objectives: to evaluate the complications of induction chemotherapy in adult patients with acute myelogenous leukemia at Hue central hospital". Subject and method: 30 AML patients aged from 10 to 30 were treated at clinical hematology service, Hue central hospital from Mars, 2005 to July, 2006. The diagnosis of AML based on FAB classification. Induction therapy consisted of a combination of cytarabin 100mglm2/day given by continuous IV over 7 days and daunorubicin 45mg/m2/day for 3 days. Complications were evaluated based on toxicity grade of WHO. \r\n', u'Results: Alopecia was the most common complications (100%) but good recovery. Gastrointestinal toxicity included: nausea and vomiting (6.6%), oral mucositis (40%) and diarrhea (30%) Cerebral hemorrhage due thrombocytopenia (6.66%) and neutropenic septicemia (20%) are the most severe complications. Acute complications on cardio - vascular system were rare and only mild degree. Conclusion: The complications of induction chemotherapy in adult patients with acute myelogenous leukemia occur at many organs with different degrees. Among of them, bone marrow suppression is the most severe complication with cerebral hemorrhage due thrombocytopenia and neutropenic septicemia which are fatal complications in theses patients. \r\n', u'\r\n', u'
Leukemia ; Myeloid ; Acute/ complications ; pathology ; drug therapy

No abstract available.
Cytarabine* ; Drug Therapy, Combination* ; Leukemia, Myeloid, Acute*

Humans ; Leukemia, Myeloid, Acute/drug therapy* ; Recurrence

The overall therapeutic outcome of acute myeloid leukemia (AML) is poor, and relapse and refractory are the main reasons for treatment failure. Leukemia cells of relapsed and refractory AML (R/R-AML) patients are usually resistant to conventional chemotherapy, and new treatment regimens are urgently needed to further improve the survival rate and prolong the survival time of these patients.There are no recommended unified treatment regimens other than entering clinical trials.At present,the main options are salvage chemotherapy and hematopoietic stem cell transplantation (HSCT), and HSCT is the only possible cure for R/R-AML, but the prognosis of most of these patients is still poor.In recent years,the treatment status of AML has progressed rapidly, and the new therapies are emerging, many new drugs have become the research focus. Some progress has been made in improving chemosensitivity and overcoming chemoresistance by combining the new drugs with the original chemotherapeutic drugs, which provide a new treatment option and improve the overall prognosis for R/R-AML patients. This article will review the current treatment status and the latest progress in new drug research of R/R-AML.
Humans ; Leukemia, Myeloid, Acute/drug therapy*

Drug Delivery Systems ; Humans ; Leukemia, Myeloid, Acute ; drug therapy

Acute myeloid leukemia (AML) is a rare type of childhood acute leukemia, which has a worse prognosis than childhood acute lymphoblastic leukemia. Over the past decade, significant progress has been made in the treatment of childhood AML and the 5-year event-free survival rate may be as high as 70% in developed countries. This survival improvement is largely attributable to risk-stratified treatments, therapies tailored to individual patients based on the biological characteristics of the disease, and continuously improving supportive care. An accurate diagnosis is the prerequisite for risk stratification, prognostic evaluation and therapeutic decision making. How to reduce early mortality and thus improve overall survival, how to implement appropriate supportive treatment to reduce treatment-associated complications, and how to reduce treatment-related mortality are the key to the improvement of therapies for childhood acute myeloid leukemia.
Child ; Humans ; Leukemia, Myeloid, Acute ; diagnosis ; drug therapy ; genetics ; mortality ; Leukemia, Promyelocytic, Acute ; drug therapy ; genetics

BACKGROUND: The findings of dysplastic features in haemopoietic cells in de novo acute myeloid leukemia(AML) is defined as AML with trilineage myelodysplasia(AML/TMDS). These cases have been reported accounting for 10-5% of de novo AML. The rate of complete remission(CR) in AML/TMDS to conventional chemotherapy is poor and relapse occur much earlier than in patients without dysplastic features. TMDS features are also observed during remission and termed this de novo AML with myelodysplastic remission marrow(AML/MRM). Recent report described that TMDS during remission was more closely related to prognosis than dysplastic features at diagnosis. We investigated the incidence of AML/TMDS and AML/MRM and evaluated the impending role of dysplasia in prognosis. METHOD: Ninety-ive patients with de novo AML from March 1994 to December 1998 were enrolled according to the FAB classifiction. To determine AML/TMDS and AML/MRM, we used Brito-abapulle's criteria and Kazuhiro's criteria. Prognosis was aalysed by the means of disease free survival(DFS) and overall survival(OS). RESULTS: Nine(9.5%) patients had AML/TMDS and it was 7.7%, 17.2%, 50% of patients with M2, M4 and M6. CR rate was 44.4% for TMDS patients compared to 76.7% for patients without TMDS(p<0.05). AML/TMDS also showed significantly shorter DFS and OS. The incidence of AML/MRM was higher in the group of AML/TMDS(44.4%) compared to AML without TMDS(8.1%) but was not related to prognosis. CONCLUSION: We concluded that the presence of TMDS in de novo AML exerts a negative effect on the ability to achieve CR and in the prognosis. But the MRM has no significance to predict poor prognosis and early relapse.
Diagnosis ; Drug Therapy ; Humans ; Incidence ; Leukemia, Myeloid, Acute* ; Prognosis ; Recurrence